Reduced-Dose Chemotherapy for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, stable doses of anti-seizure medications are allowed if your CNS disease is treated and stable. It's best to discuss your specific medications with the trial team.
Is reduced-dose chemotherapy for lung cancer safe for humans?
Docetaxel, when combined with other drugs like cisplatin or carboplatin, is generally well-tolerated in treating lung cancer. The main side effect is neutropenia (a drop in white blood cells), but severe nerve damage and kidney problems are uncommon. Other combinations with docetaxel, such as with gemcitabine or irinotecan, also show manageable side effects, making these treatments generally safe for humans.12345
What makes the reduced-dose chemotherapy treatment for lung cancer unique?
The reduced-dose chemotherapy treatment for lung cancer is unique because it combines multiple drugs like Carboplatin, Docetaxel, and others, potentially reducing side effects while maintaining effectiveness. This approach may offer a better balance between treatment efficacy and tolerability compared to standard-dose regimens.23567
What data supports the effectiveness of the drug combination used in the Reduced-Dose Chemotherapy for Lung Cancer trial?
Research shows that the combination of paclitaxel and carboplatin has been effective in treating non-small cell lung cancer, with response rates up to 48% and 1-year survival rates as high as 54%. Additionally, the combination of docetaxel and carboplatin has shown promising activity with a 48% response rate, indicating potential effectiveness for lung cancer treatment.4891011
Who Is on the Research Team?
Julia Judd, DO
Principal Investigator
Fox Chase Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with stage IV lung cancer (small cell or non-small cell) or inoperable stage III. They may have had previous treatments and can have stable, treated brain metastases. Participants must be able to perform daily activities (ECOG 0-3), not be pregnant, agree to use contraception, and plan to receive one of the listed chemotherapy drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dose attenuated chemotherapy regimens based on their comorbidities and age
Follow-up
Participants are monitored for safety, efficacy, and progression-free survival
Open-label extension (optional)
Participants may continue to receive treatment and be monitored long-term
What Are the Treatments Tested in This Trial?
Interventions
- Carboplatin
- Docetaxel
- Gemcitabine
- Irinotecan
- Lurbinectedin
- Nab paclitaxel
- Paclitaxel
- Pemetrexed
- Topotecan
Carboplatin is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fox Chase Cancer Center
Lead Sponsor